Delivery Order SPE2DR25D2103-SPE2DR26F91QD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 MG/ML auto-injector supplies, with a ceiling value of $3,082.67. This non-competitive delivery order, issued on October 28, 2025, carries a completion deadline of November 19, 2025. The award employs firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply relationship. Performance will be executed from the company's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 19, 2025, with an ultimate completion date of October 10, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,330.68 for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector pharmaceutical product, valued at $9,975.58, with a firm fixed price structure. This delivery order, issued on May 6, 2025, is classified as a child contract under a larger vehicle and carries an ultimate completion date of May 28, 2025. The award represents a non-competitive delivery order executed under AmerisourceBergen's existing indefinite delivery contract framework...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 28, 2025, with completion expected by September 19, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and represents a competitive award to the pharmaceutical distributor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector, with an ultimate completion date of October 3, 2025. This non-competitive, firm fixed-price delivery order was issued on September 12, 2025, under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price contract represents a non-competitive delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on September 5, 2025. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of September 26, 2025. The award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injector on August 19, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified vendors in the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,082.67 firm fixed-price delivery order for BENLYSTA 200 MG/ML auto-injector on July 30, 2025, with a completion date of August 20, 2025. The award is not set-aside and represents a competitive procurement for the pharmaceutical supply to support federal medical needs. Performance will occur at AmerisourceBergen's Conshohocken, Pennsylvania facility, and this delivery order is issued under a larger contract vehicle with the...
- SPE2DR25D2103Indefinite Delivery Contract
- SPE2DR25D2103-SPE2DR26F91QDDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $12,994.64 firm fixed-price delivery order for BENLYSTA 200 mg/ml auto-injector on November 10, 2025, with completion due by December 3, 2025. The award, issued without set-aside designation, reflects a competitively awarded transaction for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through the Defense Logistics Agency's medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. BENLYSTA, a biologic medication for systemic lupus erythematosus, represents a specialized pharmaceutical commodity within the broader therapeutic domains covered under this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 11/10/25 |